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Abstract
Summary The study aimed to achieve expert consensus to optimize secondary fracture prevention in Spain. Relevant gaps in
current patient management were identified. However, some aspects were considered difficult to apply. Future efforts should
focus on those items with greatest divergences between importance and feasibility.
Purpose To establish a Spanish multidisciplinary expert consensus on secondary fracture prevention.
Methods A two-round Delphi consensus was conducted, guided by a Scientific Committee. The 43-item study questionnaire was
designed from a literature review and a subsequent multidisciplinary expert group (n = 12) discussion. The first-round question-
naire, using a 7-point Likert scale, assessed the experts’ opinion of the current situation, their wish for items to happen, and their
prognosis that items would be implemented within 5 years. Items for which consensus was not achieved were included in the
second round. Consensus was defined as ≥ 75% agreement or ≥ 75% disagreement. A total of 102 experts from 14 scientific
societies were invited to participate.
Results A total of 75 (response rate 73.5%) and 69 (92.0%) experts answered the first and second Delphi rounds, respectively.
Participants mean age was 51.8 years [standard deviation (SD): 10.1 years]; being 24.0% rheumatologists, 21.3% primary care
physicians, 14.7% geriatricians, 8.0% internal medicine specialists, 8.0% rehabilitation physicians, and 8.0% gynecologists.
Consensus was achieved for 79.1% of items (wish, 100%; prognosis, 58.1%). Effective secondary prevention strategies identified
as requiring improvement included: clinical report standardization, effective hospital primary care communication (telephone/
mail and case managers), health-related quality of life (HRQoL) questionnaires use, and treatment compliance monitoring
(prognosis agreement 33.3%, 47.8%, 18.8%, and 55.1%, respectively).
Conclusion A consensus was reached by health professionals in their wish to implement strategies to optimize secondary fracture
prevention; however, they considered some difficult to apply. Efforts should focus on those items with currently low application
and those with greatest divergence between wish and prognosis.
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Introduction
Population aging is boosting osteoporosis (OP) and fragility
fracture incidence [1]. These fractures represent a high burden,
being associated with significant morbidity, mortality, and
healthcare costs [1, 2]. Following major fractures, almost half
of patients, particularly the elderly, never regain previous
function; one-third requiring important changes to their living
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environments; and hip fractures are associated with a two- to
three-fold increase in mortality [2]. Additionally, OP diagno-
sis may lead to psychological and physical consequences,
impacting patients’ health-related quality of life (HRQoL)
[3–7].
Patients with a record of fragility fracture are at a higher
risk of new fractures compared to the general population
[8–10]. Therefore, most guidelines advise OP treatment to
reduce the number of new fractures in this cohort [11].
Numerous studies have clearly documented an important
treatment gap after a fragility fracture [1]. Although OP is a
chronic condition requiring a long-term management plan
[12], initiation of OP therapy lags behind other disease areas,
with a decrease in bisphosphonate prescription in recent years
in Europe and the USA [2, 13, 14]. Less than 20% of individ-
uals suffering a fragility fracture receive treatment within the
following year to reduce the risk of future fractures [15]. In
Spain, only 5–8% of patients with hip fracture received prior
bone protection medication, while at discharge, this percent-
age represents 21–37%, and one-month post-fracture, it is 38–
41% [16, 17]. Furthermore, patients at high risk of fractures
who are prescribed OP drugs frequently withdraw from treat-
ment within the first year [12]. In Spain, 50% of patients
register poor compliance or discontinue OP treatment during
the first year [18]. As a result, there is an important gap be-
tween patients who would benefit from treatment and those
who actually receive it [13].
Several scientific organizations have called for an improve-
ment in fragility fracture management in order to prevent sub-
sequent fractures and restore functional abilities and life qual-
ity [1]. Thus, it is time for a “call to action” to the professionals
involved in fragility fracture management.
Our study aims to reach a consensus among multidisciplin-
ary experts on the best measures required to optimize fragility
fracture management of patients in Spain.
Methods
A two-round Delphi was conducted. The Delphi method is a
systematic approach to obtain opinions of a group of experts
by means of a series of short self-administered questionnaires
[19].
Participants
To create the multidisciplinary Delphi panel of experts, the
main Spanish societies involved in fragility fracture patient
management and other osteoporosis-related associations (n =
14) participated in the study: Spanish Association for the
Study of Menopause (AEEM); Hispanic Foundation for
Osteoporosis and Metabolic Diseases (FHOEMO); Spanish
Society of Healthcare Executives (SEDISA); Spanish
Society of Endocrinology and Nutrition (SEEN); Spanish
Society of Osteoporotic Fractures (SEFRAOS); Spanish
Society of Geriatric Medicine and Gerontology (SEGG);
Spanish Society for Bone and Mineral Metabolism Research
(SEIOMM); Spanish Society of Geriatric Medicine
(SEMEG); Spanish Society of Primary Health Care
Physicians (SEMERGEN); Spanish Society of Family and
Community Medicine (SEMFYC); Spanish Society of
General and Family Medicine (SEMG); Spanish Society of
In te rna l Medic ine (SEMI) ; Span i sh Soc ie ty of
Rheumatology (SER); and Spanish Society of Rehabilitation
and Physical Medicine (SERMEF).
These societies were responsible for selecting the partici-
pants among their members. Selected participants were phy-
sicians who practiced a medical specialty related to each spe-
cific society, with expertise in osteoporotic fracture manage-
ment. Every expert received an e-mail describing the purpose
of the study and a web link to the survey.
Scientific committee
The project was led by a scientific committee comprising five
experts in fragility fractures (two rheumatologists [SEIOMM],
two general practitioners [SEMERGEN, SEMG], and one in-
ternal medicine physician [SEMI]). These members were se-
lected by the promoter of the study (SEIOMM) among the
different members of the societies collaborating in the study,
considering their expertise in fragility fractures and a multi-
disciplinary composition of the committee.
Design
The study questionnaire was designed based on a literature
review on secondary fracture prevention and a multidisciplin-
ary expert discussion group (general practitioners [n = 2];
specialists in rheumatology [n = 2]; gynecology [n = 1], inter-
nal medicine [n = 1]; geriatrics [n = 2], physical therapy [n=
1]; endocrinology [n = 1]; pharmacists [n = 1]; healthcare
managers [n = 1]) and overseen by the Scientific Steering
Committee. First-round questionnaire was available from
March 6 to April 7, 2019, while the second-round was avail-
able from May 13 to June 6, 2019.
The first-round questionnaire included sociodemographic
variables and 20 questions, comprising a total of 43 items
exploring different aspects of secondary fracture prevention
in Spain. In each question posed, the experts were asked to
express their opinion from the current perspective as well as
their wish and their prognosis regarding the future (5-year
period). Each question was scored in a 7-point Likert scale
(1, strongly disagree; 2, mostly disagree; 3, somewhat dis-
agree; 4, neither agree nor disagree; 5, somewhat agree; 6,
mostly agree; 7, strongly agree), corresponding to the extent
to which the expert agreed with the item being addressed.
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Participants were also provided with a free-text space in which
they could make observations and comments.
The second-round questionnaire comprised the questions
for which no consensus was reached in the first round. Only
the wish and prognosis perspectives were included, since the
current perspective described the present situation and did not
require consensus. This second questionnaire was tailored
specifically for each expert. Every question contained infor-
mation regarding the score he/she recorded in the first round
and the position of the overall group (range of the greatest
percentage of scores). Each expert was invited to confirm
his/her position or modify the score to bring it closer to that
of the group, so that a consensus could be reached on the
greatest possible number of questions asked.
Data analysis
For each question, consensus was achieved when at least 75%
of participants reached agreement (5, somewhat agree; 6,
mostly agree; or 7, strongly agree) or disagreement (1, strong-
ly disagree; 2, mostly disagree; or 3, somewhat disagree). The
former was referred to as “agreement consensus”, as the ma-
jority of experts wanted it to happen or predicted it would
happen, whereas the latter was called “disagreement consen-
sus”, since most experts did not want it to happen or predicted
it would not happen.
The strategies proposed with the lowest application
(current, ≥ 75.0% disagreement), requiring implementation
(wish, ≥ 75.0% agreement) but unlikely to be applied (prog-
nosis ˂ 75.0% agreement), were identified as those strategies
requiring main attention. For these strategies, consensus was
analyzed for the whole of participants but also according to
medical specialty (considering the specialties with > 10.0% of
participation in the study) and time of professional experience
(above or below average time of experience).
Results
Participants
Of the 102 experts invited to participate in the study, 75 fully
answered the first-round questionnaire (response rate 73.5%),
while 69 experts fully answered the second-round question-
naire (response rate 92.0%).
Participants average age was 51.8 years [standard deviation
(SD): 10.1 years], 60.0% men and 40.0% women, with pro-
fessional experience of 22.3 years [SD: 10.9 years]. Expert
distribution by medical specialties was as follows: rheumatol-
ogy 24.0% (n = 18), primary care (PC) 21.3% (n = 16), geri-
atrics and gerontology 14.7% (n = 11), internal medicine 8.0%
(n = 6), physical medicine and rehabilitation 8.0% (n = 6),
obstetrics and gynecology 8.0% (n = 6), endocrinology and
nutrition 6.7% (n = 5), orthopedic surgery and traumatology
4.0% (n = 3), health executive 2.7% (n = 2), and others 2.7%
(n = 2) (Table 1).
Current situation and consensus (wish and prognosis)
Consensus was reached on 79.1% of items (wish, 100%; prog-
nosis, 58.1%) (Table 2).
Education and specific policies
There are no specific educational campaigns for patients or
health policies aimed specifically at improving secondary
fracture prevention in Spain. However, most participants
(wish, 96.0%; prognosis, 82.6%) agreed that educational cam-
paigns for patients with fractures should be implemented and
would also like to have specific health policies (wish, 92.0%
both at national and regional levels), but this latter would be
unlikely to happen mid-term (agreement 65.2% at national
and 43.5% at regional level, respectively).
The main agents involved in educational campaigns are the
pharmaceutical industry and scientific societies, while
healthcare managers are the least involved, according to par-
ticipants. Participants agreed that all agents should be in-
volved in educational campaigns, considering that the phar-
maceutical industry (prognosis, 96.0%), scientific societies
(prognosis, 93.3%), and health professionals (prognosis,
80.0%) should be involved. However, mid-term involvement
of patient associations, media, and healthcare managers was
deemed to be less probable.
Strategies to improve care/compliance
Application of the seven strategies proposed (promotion of
healthy lifestyle and fall prevention, treatment prescription
optimization, implementation of fracture liaison services
(FLS) or specific resources for fracture patients, patient infor-
mation/training, promotion patient-physician communication,
continuous training of healthcare personnel, promotion of
social/family support) to improve patient care and/or treat-
ment compliance in secondary fracture prevention varies.
Patient information or social support promotion is the least
common. Although participants agreed that all the strategies
should be put into practice to improve fracture patient care,
only the promotion of healthy lifestyle and prevention of falls
(prognosis, 87.0%), OP treatment optimization (prognosis,
81.2), FLS or other specific strategies implementation (prog-
nosis, 79.7%), and patient information (prognosis, 76.8%)
were considered feasible for mid-term implementation.
Experts considered that the implementation of specific re-
sources for fracture patients, such as FLS, contributes to pa-
tient control and health resource saving and agreed it improves
patient follow-up (wish, 96.0%; prognosis, 89.9%).
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Table 1 Sociodemographic
variables of participants Variable Value





SEIOMM: Spanish Society for Research on Bone and Mineral Metabolism 57.3% (43)
SER: Spanish Society of Rheumatology 25.3% (19)
SEFRAOS: Spanish Society of Osteoporotic Fractures 17.3% (13)
SEMERGEN: Spanish Society of Primary Health Care Physicians 14.7% (11)
SEMEG: Spanish Society of Geriatric Medicine 12.0% (9)
SEGG: Spanish Society of Geriatric Medicine and Gerontology 10.7% (8)
SEMG: Spanish Society of General and Family Medicine 10.7% (8)
AEEM: Spanish Association for the Study of Menopause 10.7% (8)
FHOEMO: Hispanic Foundation for Osteoporosis and Metabolic Diseases 9.3% (7)
SERMEF: Spanish Society of Rehabilitation and Physical Medicine 9.3% (7)
SEMI: Spanish Society of Internal Medicine 8.0% (6)
SEDISA: Spanish Society of Healthcare Executives 6.7% (5)




Primary care 21.3% (16)
Geriatrics and gerontology 14.7% (11)
Internal medicine 8.0% (6)
Physical medicine and rehabilitation 8.0% (6)
Obstetrics and gynecology 8.0% (6)
Endocrinology and nutrition 6.7% (5)
Orthopedic surgery and traumatology 4.0% (3)
Health executive 2.7% (2)
Others 2.7% (2)
Mean time of professional experience, years (SD) 22.3 (10.9)
Hospital type [%(N)]^
Group 1: < 200 beds 10.6% (7)
Group 2: 200–500 beds 31,8% (21)
Group 3: 501–1000 beds 25.8% (17)
Group 4: > 1000 beds 30.3% (20)
Not applicable 1.5% (1)
Specific resources for fracture patients at the hospital [%(N)]^
Fracture liaison service (FLS) 33.3% (22)
Others 25.8% (16)
Orthogeriatric unit 13.6% (9)
Specific osteoporosis or bone metabolism unit 4.5% (3)
Close cooperation with orthopedic surgery and traumatology service 3.0% (2)
Fracture unit 1.5% (1)
FLS in development 1.5% (1)
None 36.7% (18)
Not applicable 3.0% (2)
*Participants could be members of more than one scientific society
^Questions answered by 66 out of 75 participants
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Table 2 Results of the Delphi consultation: current, wish and prognosis perspectives
Question Current (%)* Wish (%) Prognosis (%)
D I A D I A D I A
1. Specific educational campaigns are carried out for patients who have suffered a fragility
fracture
64.0 4.0 32.0 2.7 1.3 96.0 11.6 5.8 82.6
2. The following agents and/or groups are involved in awareness and educational campaigns





























































3. There are specific health policies for the improvement of secondary prevention of fragility
fractures:
3.1 At the national level



















4. The following strategies are applied to improve care and/or compliance in the secondary
prevention of fragility fractures
4.1 Promotion of healthy lifestyle and fall prevention
4.2 Treatment prescription optimization
4.3. Implementation of fracture liaison services (FLS) or specific resources for fracture patients
4.4 Patient information/training
4.5 Promotion patient-physician communication
4.6 Continuous training of healthcare personnel
































































5. The implementation of specific resources for the patient with fragility fracture (such as FLS)
allows for better control and follow-up of patients and for resources savings for the health
system by reducing the number of new fragility fractures.
26.7 13.3 60.0 2.7 1.3 96.0 4.3 5.8 89.9
6. The different clinical practice guidelines define standardized criteria for secondary
prevention of fragility fractures.
25.3 4.0 70.7 0 2.7 97.3 4.0 10.7 85.3
7. To prevent a new fracture, all patients with fragility fracture receive:
7.1 Recommendations on healthy measures and habits
7.2 Active pharmacological treatment for osteoporosis
7.3 Recommendations on Calcium and Vitamin D Supplements





































8. The "treat-to-target" strategy is applied in the secondary prevention of fragility fractures 73.3 14.7 12.0 10.7 10.7 78.7 31.9 14.5 53.6
9. When discussing treatment for secondary fracture prevention, the patient receives clear and
concise information from the primary care physician or hospital:
9.1 The importance of therapeutic compliance
9.2 Fracture status and prognosis




























10. In routine clinical practice, a systematic control of treatment compliance is performed for the
secondary prevention of fragility fractures**
80.0 6.7 13.3 2.7 1.3 96.0 34.8 10.1 55.1
11. Systematic recording of fragility fractures in the patient's medical record allows better
identification and secondary prevention of fragility fractures
28.0 12.0 60.0 1.3 2.7 96.0 0 5.8 94.2
12. There is a registry of fragility fractures:
12.1 At the national level



















13. There is an efficient communication system between hospital and primary care that allows
effective follow-up of the fracture patient, through
13.1 Shared health record
13.2 Telephone and/or specific e-mail address between assistance levels**




























14. After a fragility fracture, the hospital doctor sends a report to the primary care doctor
proposing the most appropriate specific treatment.
65.3 8.0 26.7 2.7 2.7 94.7 8.7 13.0 78.3
15. The clinical reports of the fracture patient sent from hospital to primary care are standardized
at the hospital level**
86.7 5.3 8.0 2.7 4.0 93.3 52.2 14.5 33.3
16. There are protocols for the treatment of the patient with fragility fracture, in the case of:
16.1 Hip fracture (specific protocol) 25.3 5.3 69.3 1.3 4.0 94.7 9.3 4.0 86.7
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Approaches to prevent fractures
Most experts considered that the criteria for secondary fracture
prevention in clinical guidelines are standardized (wish, 97.3%;
prognosis, 85.3%). However, currently, not all patients with
fragility fracture are optimally managed to prevent new frac-
tures. Participants considered the provision of OP treatment
both necessary and feasible (wish, 96.0%; prognosis, 78.3%),
recommendations on calcium and vitamin D intake (wish,
93.3%; prognosis, 77.3%) or healthy lifestyle promotion (wish,
96.0%; prognosis, 85.5%), while a specific rehabilitation pro-
gram for preventing falls was found to be difficult to implement
(wish, 93.3%; prognosis, 69.6%). A “treat-to-target” strategy is
not currently applied, and although it was regarded as important
(wish, 78.7%), experts considered that the situation would not
change in the short term (prognosis, 53.6%).
At present, health professionals do not provide appropriate
information to the patient about the state and prognosis of the
fracture, the risk-benefit of therapeutic options, nor the impor-
tance of treatment compliance. Participants agreed that this
information should be provided to the patient though fewer
thought the benefit-risk balance of treatment options would be
implemented mid-term (prognosis, 72.5%).
Finally, OP treatment compliance is not currently assessed in
a systematic fashion, and despite its relevance (wish, 96.0%),
participants believed it would remain so (prognosis, 55.1%).
Fracture identification
Experts considered that fracture coding in medical history con-
tributes to the prevention of new fractures, since it facilitates
identification. In accordance with the current situation, partici-
pants agreed (wish, 96.0%; prognosis, 94.2%) that better sec-
ondary fracture prevention could be achieved by systematically
recording fragility fractures in the clinical chart.
National or regional fracture registries are not widespread
in Spain. However, while participants considered that national
registries should and would be established (wish, 93.3%;
prognosis, 78.3%), they perceived that regional registries
would be implemented less (prognosis, 49.3%).
Hospital-primary care communication
In general, no effective communication systems between the
hospital and PC exist for patient follow-up. Although the par-
ticipants agreed that the three strategies proposed (specific
telephone/e-mail, case manager and shared health record)
should be used, they considered that only communication
through shared health records was feasible (prognosis,
80.0%).
The content of the fracture patient’s clinical report is not
standardized among hospitals, and it is not referred to PC.
Participants agreed (wish, 94.7%; prognosis, 78.3%) that a
clinical report, including treatment recommendation, should
and would be submitted to PC at patient discharge.
However, it would not be feasible to standardize the minimum
measures to be implemented mid-term (prognosis, 33.3%).
Treatment protocols
Experts considered that treatment protocols are not wide-
spread in Spain. Accordingly, although participants reflected
Table 2 (continued)
Question Current (%)* Wish (%) Prognosis (%)
D I A D I A D I A
16.2 Fragility fractures in general
16.3 Vertebral fracture (specific protocol)




























17. In long-term follow-up of the patient, there is an established protocol about "drug holidays"
(drug treatment rest periods) of bisphosphonates and restoration of medication in treatment
for secondary prevention of fragility fractures.
54.7 10.7 34.7 5.3 2.7 92.0 13.0 10.1 76.8
18. In making decisions about treatment for secondary fracture prevention, the health
professional considers the patient's preferences
40.0 9.3 50.7 1.3 6.7 92.0 10.1 7.2 82.6
19. To promote patient involvement, there are specific tools (patient-directed informational
material, in paper or on-line format) to assist decision-making on treatment for secondary
prevention of fragile fractures
52.0 14.7 33.3 5.3 6.7 88.0 5.8 13.0 81.2
20. In clinical practice, questionnaires are used to assess the health-related quality of life
(HRQoL) of the patient with fragility fracture**
85.3 5.3 9.3 6.7 12.0 81.3 65.2 15.9 18.8
D disagreement, I indifference, A agreement
Wish (desire for it to happen); prognosis (belief that it will happen in a five-year period)
*Current perspective was not subject to formal consensus
**Strategies requiring main attention
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there should be established protocols for all fracture profiles,
protocols for the treatment of other fractures (humerus, wrist,
etc.) would not be developed mid-term (prognosis, 66.7%).
“Drug holidays” related to bisphosphonate treatment are
not generally addressed by existing protocols; nonetheless,
participants considered they would be in the future (wish,
92.0%; prognosis, 76.8%).
Patient perspective
Only half of the experts expressed that treatment-related deci-
sion-making considers patient preferences and that patient de-
cision aids are available for a shared decision-making. On the
other hand, patient HRQoL is not assessed in current clinical
practice. Participants agreed that patient preferences would be
taken into greater consideration in the future (wish, 92.0%;
prognosis, 82.6%) and decision aids to promote patient in-
volvement would become available mid-term (wish, 88.0%;
prognosis, 81.2%). The use of HRQoL questionnaires was
considered necessary (wish, 81.3%), but not likely in the near
future (prognosis, 18.8%).
Strategies requiring main attention
The consensus reached for the whole of participants regarding
the four strategies requiring main attention (Table 2) is main-
tained (current: ≥ 75.0% disagreement, wish: ≥ 75.0% agree-
ment, prognosis: no consensus) when analyzed by medical
specialty (rheumatology vs. PC vs. geriatrics and gerontology)




In this Delphi survey, a multidisciplinary group of experts in
the field of osteoporotic fractures agreed on the measures to be
adopted to optimize the management of patients with fragility
fractures. The findings of our study indicate the changes re-
quired to improve secondary fracture prevention in routine clin-
ical practice. Likewise, these results provide key information to
help stakeholders anticipate future hurdles and unmet needs in
the management of patients with fragility fractures in Spain.
Participants agreed on the need to apply all the strategies
proposed (wish), which highlights health professionals’ inter-
est in improving current secondary fracture prevention strate-
gies. However, regarding their prognosis of future implemen-
tation, consensus was only reached for 58.1% of questions.
This means that although experts consider the proposed strat-
egies are necessary, around 40% are deemed unlikely to be
implemented.
To overcome the current barriers for effective secondary
fracture prevention, attention should be paid to the following
strategies, which are currently the least implemented and
whose implementation is considered unlikely mid-term: (1)
standardization of the clinical reports of fracture patients
discharged from hospital; (2) implementation of effective
communication channels between hospital and primary care,
such as a specific telephone/e-mail or a case manager, for
patient follow-up; (3) use of HRQoL questionnaires to con-
sider patient perspective in treatment decision-making; and (4)
systematic control of OP treatment compliance.
Other recommendable strategies with currently low applica-
tion are the involvement of healthcare managers in educational
campaigns, the development of specific healthcare policies for
fracture prevention, the promotion of social support initiatives
to improve patient care, and the establishment of national frac-
ture registries. Finally, the following are also considered rele-
vant: the implementation of fall prevention programs, the pro-
vision of patient information about the risk-benefit of the ther-
apeutic options, the existence of protocols for the treatment of
non-hip-non-vertebral fractures, and the implementation of a
treat-to-target strategy to optimize treatment.
Results in the context of existing literature
In 2016, leading researchers and bone health experts from
different foundations met at the ASBMR Annual Meeting
and issued a call to action with recommendations to assertive-
ly address the critical care gap and reduce fracture risk in our
aging population [20]. Since this meeting, many other health
organizations have joined, urging the case for promoting the
prevention of second and subsequent fractures in patients who
have sustained their first fragility fracture [21].
In response to this call to action, our study has identified the
main issues that should be addressed in Spain to optimize
fracture prevention. Changes in clinical practice should be
performed to address the current management gaps identified,
and efforts should focus on those items reflecting the greatest
divergence between importance (wish) and feasibility (prog-
nosis). In agreement with our results, previous studies have
highlighted the need to optimize coordination between prima-
ry and specialized care [22, 23], which becomes important
after an osteoporotic fracture has been repaired [24].
Currently, the patient-centered approach to decision-making
is a hot topic, and this has also arisen as a major issue in our
study. The care community should gain a better understanding of
the patient’s fragility fracture experience so that direct improve-
ments in care can be based on the perspectives of end users [25].
As a consequence of this gap, there is little social awareness of
OP and fragility fractures [26], and many patients do not under-
stand the long-term significance and importance of their fracture
[27]. Thus, there is a major need to improve patient information
about the disease and the importance of treatment, with the aim
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of improving long-term OP treatment compliance [26]. In this
regard, several drugs have demonstrated to be safe and effective
in reducing the risk of fractures [28], so there is a major oppor-
tunity to involve patients in decision-making to find a treatment
option matching their preferences (e.g., administration mode). A
systematic control of treatment compliance was also found to be
an important factor in our study. This agrees with the patients’
perspective, as women with OP perceive that the condition
should be taken seriously and strategies for remembering to take
medication are necessary [29]. Interventions targeting osteopo-
rotic fracture prevention that encourage collaboration between
patients and healthcare professionals could incorporate ap-
proaches for shared decision-making or other similar approaches
to achieve medication compliance and patient education. Shared
decision-making is reported as the most effective therapeutic
option to increase medical treatment compliance and persistence,
as well as fostering greater patient satisfaction and improving the
healthcare processes and outcomes for patients [30].
In line to improve fracture patient care and compliance
experts considered, the implementation of specific resources
for fracture patients, such as FLS, is feasible in mid-term. FLS
are care-coordinator-based secondary fracture prevention pro-
grams that systematically identify fragility fracture patients
and treat them [31]. Their implementation contributes to an
effective communication between the hospital and PC and
ensures continuity of care [26, 32]. Several studies indicated
that they are a cost-effective strategy for reducing the OP care
gap, refracture rate, and mortality [33, 34].
According to expert opinion, the study also pinpointed the
need for better communication with patients regarding fracture
risk and fracture risk reduction, the benefits and risks of receiving
treatment or not, and the importance of a healthy lifestyle [32]. A
multisector effort is required to support patients and their clini-
cians in undertakingmeaningful discussions on these issues [26].
This point is highly relevant, given that the lack of communica-
tion between healthcare providers and patients is frequently iden-
tified as a key barrier to proper OP management and secondary
fracture prevention [32].
With regard to prioritization of fragility fracture prevention in
national policy, there is much to be done [26]. Successful trans-
formation of care is a matter of healthcare policy and also relies
upon consensus among all participants in the multidisciplinary
team that cares for fragility fracture patients [35]. Therefore, the
recommendations provided are intended not only to help clini-
cians in patient management but also assist policy-makers in the
design and implementation of strategies and pave the way for
future research. In this respect, there is a need to create the nec-
essary structure and to provide resources so that the issue becomes
a matter of the health system rather than of the physician. Specific
polices should be made to help achieve the goals of this call to
action, with the participation of all the stakeholders involved.
Fall prevention is another currently neglected issue [1],
which the study participants considered unfeasible to
implement mid-term, and therefore, it should be addressed in
clinical practice. Many patients suffering a fall, even if unin-
jured, develop a fear of falling and tend to limit their activity,
resulting in reduced mobility, and loss of bonemass and phys-
ical fitness [36]. The COVID-19 pandemic has undoubtedly
had, and will continue to have, a significant impact on the
lives of people living with OP. Social distancing and self-
isolation are likely to be resulting in changes in activity levels
(and consequently may impact rates of falls and fractures)
[37]. Fall prevention needs comprehensive management, in-
cluding nutrition, prescription medicine, changes in lifestyle,
and exercise schedules, among others [36].
Finally, if healthcare providers and decision-makers are un-
aware of a patient’s fracture record and diagnosis with OP, they
cannot take steps to provide the long-term care required for this
lifelong, chronic condition [27]. Therefore, experts point out
that systematically recording fragility fractures in the clinical
chart facilitates patient identification and contributes to the pre-
vention of new fractures. Specific fracture registries are needed
at both the national and local (regional) levels. The Spanish
National Hip Fracture Registry is a continuous registry of pa-
tients admitted for a hip fracture in a large group of Spanish
hospitals, and recent publications suggest that it is gaining mo-
mentum [38, 39]. For instance, in the UK, clinical data for each
patient are captured and stored in Clinical Practice Research
Datalink (CPRD), one of the world’s largest databases of pri-
mary care electronic health records [40], including reliable re-
cording of fracture events [41].
The WHO has designated the period 2020–2030 as the
Decade of Healthy Aging. If the mobility and independence
of older people are to be maintained as a new demographic era
develops, a determined effort must be made to fulfill many of
the “wishes” identified.
Implications for practice and further research
The agreed strategies to optimize fracture prevention could be of
value not only for helping clinicians to manage their patients but
also for OP-related researchers, and for policy-makers to imple-
ment changes in current clinical practice in Spain. Endorsement
of the proposed strategies within national healthcare policies and
advocacy programs can achieve alignment of the objectives of
professionals, policy-makers, and patients [35].
Additionally, the results of our study contribute to antici-
pating future needs and providing a basis for further discus-
sions on how to achieve secondary fracture prevention. Other
countries could benefit from replicating this approach.
Strengths and limitations of the study
An important aspect of the Delphi technique is the choice of
an appropriate panel of participants. In this study, our aim was
to obtain a sample representing all medical specialties (and
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their respective scientific societies) involved in the manage-
ment of fragility fractures. Therefore, the multidisciplinary
composition of the Delphi panel, together with their vast pro-
fessional experience, is one of the main strengths of the study,
as it brings a wide range of expertise and experience to the
decision-making process. It is of great value that healthcare
executives and professionals from different specialties and
scientific societies have reached a common consensus and
thus reflect unmet needs in OP management. Regarding the
number of participants in our Delphi study, we consider it to
be sufficient given a minimum of 10–18 panel members have
been suggested by other authors [42].
Another strength lies in the fact that the questionnaire was
drawn up under the guidance of a scientific committee and the
expert discussion group, helping to define the appropriate and
inappropriate approaches to current gaps in care. Consequently,
the questions posed were relevant to participants and facilitated
a consensus regarding the professionals’wishes. Of note, some
of the strategies identified may refer to unmet needs related to
the health system and thus could apply to different health con-
ditions. Nonetheless, their specific relevance in secondary frac-
ture prevention was established in this study.
One limitation is that the study was performed in Spain;
therefore, the results should be interpreted in their context and
may not be applicable to other settings. It would be interesting
to undertake a similar study using the Delphi methodology
with international experts and to compare the results.
Another limitation is the arbitrary consensus cut-off. We
decided to set the level of consensus at ≥ 75%, a threshold
frequently reported in the literature. The use of another thresh-
old could give rise to different results.
Conclusion
In this Delphi survey, a multidisciplinary group of experts from
14 different societies reached a consensus on strategies that
could be implemented to improve secondary fracture preven-
tion in Spain. Efforts should focus on those itemswith currently
low application and for which there is greatest divergence be-
tween participants’ wishes and prognosis. Accordingly, the
main items requiring improvement are the standardization of
clinical reports of fracture patients, efficient communication
between hospitals and PCs for patient follow-up, the use of
HRQoL questionnaires to consider the patient's perspective,
and the systematic monitoring of OP treatment compliance.
The results of this study represent the first step to optimizing
secondary fracture prevention in Spain in the future.
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